Skip to main content
SpringerLink
Log in

Structural imaging markers for therapeutic trials in Alzheimer’s disease

  • Structural Imaging Markers for Therapeutic Trials in Alzheimer’s Disease
  • Published:
JNHA - The Journal of Nutrition, Health and Aging

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002 May;1(1):13–21.

    Article  PubMed  Google Scholar 

  2. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007 Mar 13;68(11):828–836.

    Article  PubMed  CAS  Google Scholar 

  3. Desikan RS, Fischl B, Cabral HJ, Kemper TL, Guttmann CR, Blacker D, Hyman BT, Albert MS, Killiany RJ. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology. 2008 Sep 9;71(11):819–825

    Article  PubMed  CAS  Google Scholar 

  4. Du AT, Schuff N, Kramer JH, Ganzer S, Zhu XP, Jagust WJ, Miller BL, Reed BR, Mungas D, Yaffe K, Chui HC, Weiner MW. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology. 2004 Feb 10;62(3):422–427.

    PubMed  CAS  Google Scholar 

  5. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol. 2006 Oct;5(10):828–834.

    Google Scholar 

  6. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000 Mar;57(3):339–344.

    Article  PubMed  CAS  Google Scholar 

  7. Jack CR Jr, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004 Feb 24;62(4):591–600.

    PubMed  Google Scholar 

  8. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005 May 10;64(9):1563–1572.

    Article  PubMed  CAS  Google Scholar 

  9. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Thompson P, Fox NC. A meta-analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol Aging. 2008 Mar 15. [Epub ahead of print]

  10. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Toga AW, Jack CR Jr, Schuff N, Weiner MW, Thompson PM; The Alzheimer’s Disease Neuroimaging Initiative. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer’s disease, mild cognitive impairment, and elderly controls. Neuroimage. 2008 Nov 8. [Epub ahead of print]

  11. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology. 2005 Jul 12;65(1):119–124.

    Article  PubMed  CAS  Google Scholar 

  12. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, Rossor MN, Fox NC. Combining short interval MRI in Alzheimer’s disease: Implications for therapeutic trials. J Neurol. 2006 Sep;253(9):1147–1153.

    Article  PubMed  CAS  Google Scholar 

  13. Smith SM, Rao A, De Stefano N, Jenkinson M, Schott JM, Matthews PM, Fox NC. Longitudinal and cross-sectional analysis of atrophy in Alzheimer’s disease: crossvalidation of BSI, SIENA and SIENAX. Neuroimage. 2007 Jul 15;36(4):1200–1206. Epub 2007 Apr 27.

    Article  PubMed  Google Scholar 

  14. Grundman M and Black R. Clinical trials of Bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer’s disease. Alzheimer’s and Dementia. 2008 July; 4(4) Suppl 2:T166

    Article  Google Scholar 

  15. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol. 2008 Apr;255(4):567–574.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK

    N. C. Fox & J. Kennedy

Authors
  1. N. C. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, N.C., Kennedy, J. Structural imaging markers for therapeutic trials in Alzheimer’s disease. J Nutr Health Aging 13, 350–352 (2009). https://doi.org/10.1007/s12603-009-0040-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12603-009-0040-y

Keywords

Search

Navigation